Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the second-costliest quintile among peers.
DWS Health and Wellness S SCHLX
- NAV / 1-Day Return 42.68 / +1.16 %
- Total Assets 303.6 Mil
-
Adj. Expense Ratio
- Expense Ratio 1.060%
- Distribution Fee Level Average
- Share Class Type No Load
- Category Health
- Investment Style Large Growth
- Min. Initial Investment 2,500
- Status Open
- TTM Yield —
- Turnover 27%
USD | NAV as of Mar 27, 2024 | 1-Day Return as of Mar 27, 2024, 10:19 PM GMT+0
Morningstar’s Analysis SCHLX
Will SCHLX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 46.8
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
UnitedHealth Group Inc | 9.55 | 27.2 Mil | Healthcare |
Eli Lilly and Co | 9.14 | 26.0 Mil | Healthcare |
Merck & Co Inc | 4.63 | 13.2 Mil | Healthcare |
Johnson & Johnson | 3.79 | 10.8 Mil | Healthcare |
Thermo Fisher Scientific Inc | 3.71 | 10.6 Mil | Healthcare |
Boston Scientific Corp | 3.61 | 10.3 Mil | Healthcare |
Novo Nordisk A/S ADR | 3.54 | 10.1 Mil | Healthcare |
AbbVie Inc | 3.18 | 9.1 Mil | Healthcare |
Abbott Laboratories | 2.95 | 8.4 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 2.68 | 7.6 Mil | Healthcare |